Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crohn s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. in rheumatoid arthritis, adalimumab has a response rate similar to methotrexate, and in combination, it nearly doubles the response rate of methotrexate alone.adalimumab is a tnf-inhibiting, anti-inflammatory, biologic medication. it binds to tumor necrosis factor-alpha (tnf alfa), which normally binds to tnf alfa receptors, leading to the inflammatory response of autoimmune diseases. by binding to tnf alfa, adalimumab reduces this inflammatory response. because tnf alfa is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections.